Replies to post #6544 on MediPharm Labs Corp (MEDIF)

[FUNMAN]

Seriously? I like the PT though! See it at the end. Canadian Cannabis Stocks To Watch Before Next Week
Article

Paid press release content from MarijuanaStocks.com. The StreetInsider.com news staff was not involved in its creation.

https://www.streetinsider.com/MarijuanaStocks.com/Canadian+Cannabis+Stocks+To+Watch+Before+Next+Week/18298496.html


April 22, 2021 4:50 PM EDT

For the past two days leading marijuana stocks have begun to show signs of upward momentum in the market. Living up to their past market volatility the best cannabis stocks to invest in have seen a substantial market fluctuation in 2021. After rallying at the top of the year the cannabis sector has been seeing a decline in the market since reaching a new high on February 10th.

Because of this pullback, many leading pot stocks are trading at much lower levels in the market. Actually, most of the best cannabis stocks to buy are trading around levels they have not seen since December 2020. On the other hand, cannabis companies have been reporting record revenue growth for full-year 2020 financials. In addition, most are also giving 2021 revenue guidance that predicts more growth for this year.

Currently, in the U.S. the rapid expansion is contributing to the growth and every cannabis company is gunning for a piece of the market share. Outside the U.S. Canadian cannabis companies are also moving into a position to establish a presence. Most have done this through strategic acquisitions and partnerships that have put them closer to the U.S. cannabis market. Although unable to sell marijuana legally in the US some have established distribution with CBD products.

Canadian Marijuana Stocks In 2021

At the top of 2021 leading Canadian cannabis stocks saw the most momentum in the market. As the hopes for instant cannabis reform wore off, they have also seen the sharpest declines in the market. With many analysts beginning to feel marijuana stocks are closing on a rebound in the market it could be time to find cannabis stocks for your watchlist. For new investors doing your own due diligence will help you achieve the best positions in the current market. In general, this intel's researching a company's earnings and watching the stock's performance in the market.

With the intention of finding top marijuana stocks that can produce gains in 2021, we can look at some options. At current levels, these cannabis stocks could have future value once the cannabis sector begins to climb higher. For new traders, the cannabis market could be at levels that produce future market gains. Putting some to pot stocks on your watchlist going into the last week in April could be a portfolio game changer.

Marijuana Stocks To Watch:

Canopy Growth Corporation (NASDAQ: CGC)
MediPharm Labs Corp. (OTC: MEDIF)

Canopy Growth Corporation

Canopy Growth Corporation is one of the largest Canadian cannabis companies with a wide variety of high-quality products for both the medicinal and recreational cannabis markets. After a large investment and partnership with Constellation Brands, Inc. (NYSE: STZ) the company became one of the top Canadian marijuana stocks to watch. By its latest earnings report Canopy saw third-quarter fiscal 2021 results with a record net revenue of $153 million. Additionally, Canopy also announced it expects to achieve profitability by 2022.

Earlier in April Canopy entered into an agreement to acquire Supreme Cannabis Company, Inc. (OTC: SPRWF). Specifically, the deal is valued at $435 million in an all-stock deal that gives Supreme Cannabis shareholders Canopy shares upon completion. On April 21st Canopy signed a U.S. distribution agreement with Southern Glazer's Wine & Spirits for its CBD beverage portfolio. In detail, this partnership will support the recent launch of Quatreau the companies first line of CBD infused beverages sold in the U.S.

CGC stock is up 7.83% year to date with a high of $56.50 in February. Closing on April 22nd at the stock is down 21.13% in the last 30 days. According to analysts at CNN Business CGC stock has a 12-month median forecast price of $31.17 per share. In essence, this would be a 17.28% increase from the current market value. With this in mind, CGC stock could be one of the best Canadian cannabis stocks to invest in for 2021.



MediPharm Labs Corp.

MediPharm Labs Corp. produces purified, pharmaceutical quality cannabis oil, concentrates, and advanced derivative products. The company distributes cannabinoid-based products through its wholesale and white label distribution platforms. With the distribution of its cannabinoid-based products both domestically and internationally the company is growing globally. In March MediPharms expanded its distribution footprint in Canada and has now entered the Quebec market. Quebec included the company's now in seven provincial distribution agreements.

On April 13th MediPharms signed a supply agreement with Adjupharm that will pave the way for cannabis branded extracts in Germany. In the future, the company will supply the growing medical and wellness markets with a variety of cannabis concentrate-based products. MediPharms continues to take advantage of the growing derivatives market in Canada, Israel, and Germany.medif stock

MEDIF stock is down 7.83% year to date with a high of $0.785 in February. Currently closed on April 22nd at $0.368 the stock is down 5.78% in the last 30 days. According to analyst Market Beat MEDIF stock has a consensus price forecast of $1.38 per share. This would be an upside of 264.8%. For this reason, MEDIF stock is a top Canadian marijuana penny stock to add to your watchlist before next week.

[FUNMAN]

Gaining traction?--->>>MediPharm Labs Expands Global Portfolio in 9 Countries Including Medical and Wellness Customers for Turnkey Manufacturing and Distribution Solutions; New Supply Deal Reached With MT Pharma in Malta

MEDIF is a beat up puppy that is clawing at new growth and adding to future revenues. These are probably 6 - 9 months away. By then, some of the initial international fulfillment orders will be normalizing with higher forcastable base revenues.

IMO, things are looking much better than 36¢ in 12 months.- FUNMAN

https://www.medipharmlabs.com/news/press-releases/detail/178/medipharm-labs-expands-global-portfolio-in-9-countries

April 26, 2021

BARRIE, Ontario, April 26, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced through its wholly owned subsidiary, it has signed a new agreement with MT Pharma, based in Malta to supply premium, GMP certified, finished dose cannabis oil for patients.

MediPharm Labs continues to see significant growth opportunities ahead as numerous pharmaceutical, medical, wellness customers and brands continue to chose MediPharm as their preferred partner for turnkey GMP certified manufacturing and proven global supply chain distribution capabilities.

“The global cannabis marketplace continues to grow at a rapid pace which is prompting established pharmaceutical, wellness and brand companies to enter the industry. Many have chosen to develop products, secure a GMP certified supply chain and open distribution channels through a partnership with MediPharm,” said Keith Strachan, President and Interim Chief Executive Officer, MediPharm Labs. “We are proud to be the provider of choice for pharmaceutical and wellness companies in 9 countries and counting. These customers have contracted MediPharm to provide a turnkey solution to enhance their offerings with innovative high quality wellness products, and future potential registered pharmaceutical drugs containing cannabis, to meet patient and physician demand for personalized therapeutics and medicines.”

Under MedPharm Labs Australia Pty. Ltd.’s two year-agreement, subject to further renewals, with MT Pharma, MediPharm Labs will provide pre-formulated GMP certified full spectrum cannabis concentrates that will be distributed to patients through pharmacies that will complete final formulation and fill.

International Pharmaceutical and Medical Market Growth

MediPharm Labs is encouraged by the pace of growth in emerging international cannabis markets with large populations and strictly defined GMP regulatory frameworks for cannabis, particularly Europe, Latin America and the United States.

In the last three months, MediPharm has completed export of cannabis based derivative products to multiple customers in Germany, Peru and Australia, and has expanded its product offerings and distribution footprint in Canada. The Company expects to begin exports to other countries this year including Brazil, Malta, Denmark and New Zealand, where there are strict restrictions and in almost all cases only companies with pharmaceutical GMP certification are permitted to import product.

About MediPharm Labs

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and has fully commercialized its Australian extraction facility. MediPharm Labs Australia was established in 2017.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, significant growth opportunities ahead; global cannabis marketplace continuing to grow at a rapid pace; established pharmaceutical, wellness and brand companies to entering the industry; the Company providing a turnkey solution to enhance its partners’ offerings with innovative high quality wellness products, and future potential registered pharmaceutical drugs containing cannabis, to meet patient and physician demand for personalized therapeutics and medicines; the Company beginning exports to other countries this year including Brazil, Malta, Denmark and New Zealand; delivery of products under agreements; performance of agreements as planned; and receipt of required regulatory approvals. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.


For further information, please contact:
Laura Lepore, VP, Investor Relations and Communications
Telephone: [phone] ext. 1525
Email: [e-mail]
Website: www.medipharmlabs.com
Primary Logo

Source: MediPharm Labs Corp.
Released April 26, 2021